Spedra

Spedra is a branded erectile dysfunction medicine containing avanafil, a selective phosphodiesterase type 5 (PDE5) inhibitor. It represents a newer generation of PDE5 inhibitors, designed with higher selectivity and a faster onset of action compared to earlier medicines in the class such as sildenafil and tadalafil. Spedra is available in three strengths: 50 mg, 100 mg, and 200 mg, and is taken on demand approximately 15 to 30 minutes before sexual activity.

Faster Onset. A Key Advantage

The principal clinical advantage of avanafil over earlier PDE5 inhibitors is its rapid onset. While sildenafil typically requires 30 to 60 minutes, clinical studies have demonstrated meaningful erections in some men within 15 minutes of taking avanafil. This faster onset is attributed to avanafil's higher selectivity for PDE5 over other PDE isoforms and its pharmacokinetic profile, resulting in a rapid rise to peak plasma concentrations. For men who find the timing requirements of other PDE5 inhibitors disruptive to spontaneity and the natural flow of sexual activity, this represents a meaningful practical benefit.

Mechanism of Action

Like all PDE5 inhibitors, avanafil works by preventing the degradation of cyclic guanosine monophosphate (cGMP) in penile smooth muscle. During sexual arousal, nitric oxide released in the corpus cavernosum stimulates cGMP production, causing smooth muscle relaxation and increased blood inflow, producing an erection. By inhibiting PDE5, the enzyme that breaks down cGMP, avanafil prolongs this effect, supporting erectile function. Sexual stimulation remains a prerequisite; avanafil does not produce erections independently.

Selectivity and Tolerability

Avanafil has a higher degree of selectivity for PDE5 over PDE6 (found in retinal photoreceptors) and PDE11 (found in cardiac and skeletal muscle and testes) compared with sildenafil and tadalafil. This may translate into a reduced incidence of visual disturbances such as colour tinge, and potentially fewer musculoskeletal side effects. Clinical trials have demonstrated Spedra to be well tolerated, with headache and flushing being the most commonly reported side effects.

Spedra (avanafil) should be taken approximately 15 to 30 minutes before anticipated sexual activity. It can be taken with or without food, though high-fat meals may slightly delay the onset of action. The recommended starting dose for most men is 100 mg, with adjustment to 50 mg or 200 mg based on individual response and tolerability.

Getting the Best Results

Spedra's faster onset compared to other PDE5 inhibitors is one of its main advantages, but sexual stimulation is still required for the medicine to work. Taking Spedra 15 to 30 minutes before engaging in sexual activity, in a relaxed setting, allows the medicine to reach adequate plasma levels while retaining more spontaneity than longer-acting preparations may allow. Some men find that even 15 minutes provides sufficient time, particularly at the 200 mg dose.

Alcohol should be consumed in moderation at most when using Spedra, as it can potentiate blood pressure lowering and independently impair erectile function. Grapefruit juice should be avoided as it interferes with CYP3A4 metabolism and can increase avanafil plasma levels unpredictably.

Frequency of Use

No more than one dose of Spedra should be taken within a 24-hour period. It is not intended for daily regular dosing, though the prescriber may adjust the recommended approach based on individual needs. If Spedra is consistently ineffective at the 200 mg dose with good timing, a thorough review of contributing factors, including psychological, hormonal, and vascular causes of ED, is warranted before considering treatment alternatives.

The recommended starting dose of Spedra is 100 mg taken approximately 15 to 30 minutes before sexual activity. If this dose is well tolerated but insufficiently effective, the dose may be increased to 200 mg. If 100 mg causes troublesome side effects, reduction to 50 mg is appropriate. Only one dose should be taken in a 24-hour period.

A starting dose of 50 mg is recommended in the following situations: moderate hepatic impairment, moderate renal impairment, concurrent use of moderate CYP3A4 inhibitors (e.g. erythromycin, fluconazole), or in men aged 65 and over who may be more sensitive to hypotensive effects. The maximum dose should not exceed 100 mg in men taking moderate CYP3A4 inhibitors. Spedra is contraindicated with potent CYP3A4 inhibitors such as ketoconazole, itraconazole, and ritonavir. No dose adjustment is required for mild renal or hepatic impairment.

Common Side Effects

• Headache, the most frequently reported adverse effect, usually mild and transient
• Facial flushing and warmth
• Nasal congestion
• Nasopharyngitis (cold-like upper respiratory tract symptoms)
• Dizziness, particularly on standing
• Back pain at higher doses
• Palpitations or mild tachycardia

Serious Side Effects

• Severe hypotension with concomitant nitrate use, potentially life-threatening; this is an absolute contraindication
• Priapism, prolonged erection lasting more than 4 hours; requires immediate emergency medical attention
• Sudden loss of vision associated with NAION (non-arteritic anterior ischaemic optic neuropathy), rare but serious; discontinue immediately
• Sudden hearing loss or tinnitus (rare; stop medication and seek urgent review)
• Severe allergic reactions including rash or anaphylaxis (very rare)

Spedra must never be used concurrently with organic nitrates in any form. This includes glyceryl trinitrate (GTN) tablets, sprays, or patches; isosorbide mononitrate or dinitrate; and recreational nitrite inhalants such as amyl nitrite ("poppers"). The combination causes potentially fatal hypotension and there is no safe time window at which the two can be used together within the recommended dosing interval.

Cardiovascular Assessment

Before prescribing Spedra, clinicians should assess whether the patient has sufficient cardiovascular reserve to safely engage in sexual intercourse, as this involves a moderate degree of physical exertion. Men with unstable angina, a recent myocardial infarction or stroke (within 6 months), uncontrolled hypertension, or resting hypotension should not use Spedra without specialist cardiovascular clearance.

Alpha-blockers used for hypertension or benign prostatic enlargement may interact with avanafil to cause additional blood pressure lowering. If concurrent use is necessary, Spedra should be initiated at the 50 mg dose, patients should be warned about the possibility of dizziness on standing, and use should be timed away from alpha-blocker administration if possible.

Ocular and Hearing Cautions

Patients with a history of NAION, hereditary degenerative retinal disorders, or significant retinal vascular disease should discuss the ocular risks of PDE5 inhibitors with an ophthalmologist before using Spedra. Any sudden change in vision or hearing following a dose warrants immediate discontinuation and urgent medical review. Patients with multiple cardiovascular risk factors -- including diabetes, hyperlipidaemia, or smoking -- are at higher baseline risk of NAION and should be counselled accordingly.

• Concurrent use of organic nitrates or nitric oxide donors in any form (absolute contraindication)
• Hypersensitivity to avanafil or any excipient in the formulation
• Concurrent use with potent CYP3A4 inhibitors (ketoconazole, itraconazole, ritonavir, clarithromycin, etc.)
• Severe hepatic impairment (Child-Pugh class C)
• Cardiovascular disease where sexual activity or vasodilation would be inadvisable
• Resting hypotension (systolic below 90 mmHg)
• Uncontrolled hypertension (systolic above 170 mmHg or diastolic above 100 mmHg)
• Non-arteritic anterior ischaemic optic neuropathy (NAION) -- prior episode
• Women and children